US Patent

US8389578 — Composition and method for treating neurological disease

Method of Use · Assigned to Adamas Pharmaceuticals Inc · Expires 2028-01-22 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods and compositions for treating or preventing neurological disorders.

USPTO Abstract

The invention provides methods and compositions for treating or preventing neurological disorders.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-219 — amantadine-hydrochloride
U-3054 — amantadine-hydrochloride
U-219 — amantadine-hydrochloride
U-3054 — amantadine-hydrochloride
U-2105 — amantadine-hydrochloride
U-2105 — amantadine-hydrochloride

Patent Metadata

Patent number
US8389578
Jurisdiction
US
Classification
Method of Use
Expires
2028-01-22
Drug substance claim
No
Drug product claim
No
Assignee
Adamas Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.